The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome

被引:59
|
作者
Yilmaz, M [1 ]
Biri, A
Karakoç, A
Törüner, F
Bingöl, B
Çakir, N
Tiras, B
Ayvaz, G
Arslan, M
机构
[1] Kyrykkale Univ, Fac Med, TR-71000 Kirikkale, Turkey
[2] Gazi Univ, Fac Med, Ankara, Turkey
关键词
androgen; insulin resistance; metformin; PCOS; rosiglitazone;
D O I
10.1007/BF03345339
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The aim of this study was to assess the effects of metformin and rosiglitazone on insulin resistance and serum androgen levels in both obese and lean patients with polycystic ovary syndrome (PCOS). Materials and methods: Forty lean [body mass index (BMI) < 25 kg/m(2)] and 40 overweight and obese (BMI > 25 kg/m(2)) patients were included in the study. Waist and hip measurements, serum sex steroid levels, insulin response to 75-g oral glucose tolerance test, fasting insulin, fasting C-peptide levels and homeostasis model assessment of insulin resistance (HOMA-IR) were determined in all patients. The degree of hirsutism was determined by the Ferriman-Gallwey scoring system. Patients were divided into two groups, with 40 (20 overweight and obese; 20 non-obese) patients each. One group was treated with metformin (MET group) 850 mg bid while the other received rosiglitazone (ROSI group) 4 mg/day for 12 weeks. All measurements were repeated at the end of this period. Results: After the 12-week treatment period, HOMA-IR, area under the curve of insulin, fasting insulin and C-peptide levels were observed to have be decreased significantly in all groups. The decrease in the parameters mentioned above was similar in the four groups. The serum levels of free testosterone, androstenedione and DHEA-S decreased in all groups, but the decrease was statistically significant only in the ROSI groups. Within the lean MET group one patient became pregnant and was hence excluded from the final data analysis. Menstruations became regular after metformin therapy in 41.6% of lean and 35.7% of obese patients who had menstrual disturbance prior to the study. Rosiglitazone therapy improved menstrual disturbance in 61.5% of lean and 53.8% of obese patients. Conclusions: Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well. Rosiglitazone seemed to be more effective in decreasing the androgen levels and in achieving slightly greater improvement in menstrual disturbance than metformin.
引用
收藏
页码:1003 / 1008
页数:6
相关论文
共 50 条
  • [1] The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome
    M. Yilmaz
    A. Biri
    A. Karakoç
    F. Törüner
    B. Bingöl
    N. Çakir
    B. Tiras
    G. Ayvaz
    M. Arslan
    [J]. Journal of Endocrinological Investigation, 2005, 28 : 1003 - 1008
  • [2] The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome
    Yilmaz, M
    Bukan, N
    Ayvaz, G
    Karakoç, A
    Törüner, F
    Çakir, N
    Arslan, M
    [J]. HUMAN REPRODUCTION, 2005, 20 (12) : 3333 - 3340
  • [3] Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome
    Ortega-González, C
    Luna, S
    Hernández, L
    Crespo, G
    Aguayo, P
    Arteaga-Troncoso, G
    Parra, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03): : 1360 - 1365
  • [4] Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance
    Sepilian, V
    Nagamani, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01): : 60 - 65
  • [5] The effects of rosiglitazone on insulin resistance and oxidative stress in non-obese patients with polycystic ovary syndrome
    Bukan, N
    Yilmaz, M
    Ayvaz, G
    Karakoç, A
    Törüner, F
    Çakir, N
    Arslan, M
    [J]. CLINICA CHIMICA ACTA, 2005, 355 : S257 - S257
  • [6] The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome
    Cetinkalp, Sevki
    Karadeniz, Muammer
    Erdogan, Mehmet
    Ozgen, Gokhan
    Saygili, Fuesun
    Yilmaz, Candeger
    [J]. ENDOCRINOLOGIST, 2009, 19 (03): : 94 - 97
  • [7] The effect of combining rosiglitazone and metformin on insulin resistance in women with polycystic ovary syndrome
    Lee, K. O.
    Dong, J.
    Xin, Y.
    Tian, Y.
    Liew, S. C. F.
    Zhao, J.
    Liao, L.
    [J]. DIABETOLOGIA, 2007, 50 : S356 - S356
  • [8] Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
    Arya, Sushila
    Hansen, Karl R.
    Wild, Robert A.
    [J]. FERTILITY AND STERILITY, 2020, 113 (01) : 87 - 88
  • [9] Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance
    Song, Jinghua
    Ruan, Xiangyan
    Gu, Muqing
    Wang, Lijuan
    Wang, Husheng
    Mueck, Alfred Otto
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (05) : 413 - 417
  • [10] Effects of metformin on oxidative stress in polycystic ovary syndrome patients with insulin resistance
    Sun, Lin
    Wang, Haiyan
    Ha, Sifu
    Liu, Lina
    Wang, Huali
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 : 64 - 64